ethylmethylhydroxypyridine-succinate and Ventricular-Dysfunction--Left

We studied impact of ethylmethylhydroxypyridine succinate n the course of chronic heart failure during 3 years follow-up after myocardial infarction. Dynamics of objective and subjective parameters was assessed in 100 patients; 48 patients received conventional therapy (control group) and 52 patients received conventional therapy plus ethylmethylhydroxypyridine succinate (main group). Addition of ethylmethylhydroxypyridine succinate resulted in decreases of rates of complications, mortality, and re-hospitalizations. Increases of myocardial contractile function, myocardial adaptation, as well as improvement of range of biochemical parameters were also observed. The latter changes were indicative of antioxidant, anti-inflammatory, anti-stress activities of Ethylmethylhydroxypyridine succinate. Moreover, antidepressant and antineurotic effects of complex therapy including ethylmethylhydroxypyridine succinate was confirmed.

Topics: Antioxidants; Cardiotonic Agents; Depression; Echocardiography; Female; Health Status Indicators; Heart Failure; Humans; Male; Middle Aged; Mortality; Myocardial Contraction; Myocardial Infarction; Oxidative Stress; Patient Readmission; Pyridines; Severity of Illness Index; Treatment Outcome; Ventricular Dysfunction, Left